Autor(es):
Guseinova, Dinara ; Consolaro, Alessandro ; Trail, Lucia ; Ferrari, Cristina ; Pistorio, Angela ; Ruperto, Nicolino ; Buoncompagni, Antonella ; Pilkington, Clarissa ; Maillard, Susan ; Oliveira, Sheila K. ; Sztajnbok, Flavio ; Cuttica, Ruben ; Corona, Fabrizia ; Katsicas, Maria Martha ; Russo, Ricardo ; Ferriani, Virginia ; Burgos-Vargas, Ruben ; Solis-Vallejo, Eunice ; Bandeira, Marcia ; Baca, Vicente ; Saad-Magalhaes, Claudia [UNESP] ; Silva, Clovis A ; Barcellona, Roberto ; Breda, Luciana ; Cimaz, Rolando ; Gallizzi, Romina ; Garozzo, Rosaria ; Martino, Silvana ; Meini, Antonella ; Stabile, Achille ; Martini, Alberto ; Ravelli, Angelo
Data: 2022
Identificador Persistente: http://hdl.handle.net/11449/231258
Origem: Oasisbr
Assunto(s): Clinical features; Disease course; Drug therapy; Juvenile dermatomyositis; Onset manifestations
Descrição
Made available in DSpace on 2022-04-29T08:44:24Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-01-01
Objective: To compare the demographic features, presenting manifestations, diagnostic investigations, disease course, and drug therapies of children with juvenile dermatomyositis (JDM) followed in Europe and Latin America. Methods: Patients were inception cohorts seen between 1980 and 2004 in 27 paediatric rheumatology centres. The following information was collected through the review of patient charts: sex; age at disease onset; date of disease onset and diagnosis; onset type; presenting clinical features; diagnostic investigations; course type; and medications received during disease course. Results: Four hundred and ninety patients (65.5% females, mean onset age 7.0 years, mean disease duration 7.7 years) were included. Disease presentation was acute or insidious in 57.1% and 42.9% of the patients, respectively. The course type was monophasic in 41.3% of patients and chronic polycyclic or continuous in 58.6% of patients. The more common presenting manifestations were muscle weakness (84.9%), Gottron's papules (72.9%), heliotrope rash (62%), and malar rash (56.7%). Overall, the demographic and clinical features of the 2 continental cohorts were comparable. European patients received more frequently high-dose intravenous methylprednisolone, cyclosporine, cyclophosphamide, and azathioprine, while methotrexate and antimalarials medications were used more commonly by Latin American physicians. Conclusion: The demographic and clinical characteristics of JDM are similar in European and Latin American patients. We found, however, several differences in the use of medications between European and Latin American paediatric rheumatologists. © Clinical and Experimental Rheumatology 2011.
Istituto di Ricovero e Cura a Carattere Scientifico G Gaslini, Genova
Great Ormond Street Hospital for Children, London
UCL Institute of Child Health, London
Universidade Federal do Rio de Janeiro, Rio de Janeiro
Universidade do Estado do Rio de Janeiro, Rio de Janeiro
Hospital General de Ninos Pedro de Elizalde Buenos Aires
Hospital de Pediatria Juan P. Garrahan, Buenos Aires
Hospital das Clinicas Faculdade de Medicina de Ribeirao Preto Universidade de Sao Paulo, Ribeirao Preto
Hospital General de Mexico, Mexico City
Centro Medical National La Raza, Mexico City
Hospital Pequeno Principe, Curitiba Parana
Centro Medico Nacional Siglo XXI, Mexico City
Faculdade de Medicina de Botucatu Universitade Estadual Paulista, Botucatu
Instituto da Criança and Division of Rheumatology Faculdade de Medicina Universidade de São Paulo, São Paulo
Presidio Ospedaliera Ospedali Civili Riuniti, Sciacca
Ospedale Policlinico Università degli Studi di Chieti, Chieti
Ospedale A. Meyer, Firenze
Azienda Ospedaliera Universitaria, Messina
Università di Torino, Torino
Spedali Civili, Brescia
Università Cattolica Sacro Cuore, Rome
Università degli Studi di Genova, Genova
Faculdade de Medicina de Botucatu Universitade Estadual Paulista, Botucatu
